Ultragenyx Pharmaceutical Inc (RARE)
40.88
-0.30
(-0.74%)
USD |
NASDAQ |
May 10, 16:00
40.88
0.00 (0.00%)
After-Hours: 19:52
Ultragenyx Pharmaceutical Revenue (TTM): 442.59M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 442.59M |
| December 31, 2023 | 434.25M |
| September 30, 2023 | 410.20M |
| June 30, 2023 | 402.86M |
| March 31, 2023 | 383.89M |
| December 31, 2022 | 363.33M |
| September 30, 2022 | 343.37M |
| June 30, 2022 | 334.31M |
| March 31, 2022 | 331.95M |
| December 31, 2021 | 351.41M |
| September 30, 2021 | 359.56M |
| June 30, 2021 | 359.38M |
| Date | Value |
|---|---|
| March 31, 2021 | 334.12M |
| December 31, 2020 | 271.03M |
| September 30, 2020 | 215.08M |
| June 30, 2020 | 159.41M |
| March 31, 2020 | 121.85M |
| December 31, 2019 | 103.71M |
| September 30, 2019 | 84.38M |
| June 30, 2019 | 70.34M |
| March 31, 2019 | 58.99M |
| December 31, 2018 | 51.50M |
| September 30, 2018 | 37.65M |
| June 30, 2018 | 26.08M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
70.34M
Minimum
Jun 2019
442.59M
Maximum
Mar 2024
293.85M
Average
338.84M
Median
Revenue (TTM) Benchmarks
| Corcept Therapeutics Inc | 523.53M |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 1.403B |
| FibroGen Inc | 167.49M |
| Rocket Pharmaceuticals Inc | -- |